Zusammenfassung
Antipsychotika sind eine chemisch heterogene Gruppe von Pharmaka mit antipsychotischem Wirksamkeitsschwerpunkt und unterschiedlichem NW-Profil. Der häufig synonym verwendete Begriff »Neuroleptikum« wird international weitgehend durch den Begriff Antipsychotikum ersetzt.
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Andreasen NC, Liu D, Ziebell S et al (2013) Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013 170(6):609–615
Barnes TR, Paton C (2011) Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25(5):383–399
Choi KH, Wykes T, Kurtz MM (2013) Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry 203:172–178
Declercq T, Petrovic M, Azermai M et al (2013) Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 3:CD007726
DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde) (Hrsg) (2006) Behandlungsleitlinie Schizophrenie. Reihe: S3 Praxisleitlinien in Psychiatrie und Psychotherapie, Bd 1. Springer, Berlin Heidelberg New York
DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (2012) S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression; Langfassung Version 1.3. Januar, basierend auf der Fassung von November 2009. AWMF- Register-Nr. nvl-005
Dold M, Li C, Gillies D, Leucht S (2013) Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23:1023–1033
Fan Z, Wu Y, Shen J et al (2013) Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res 47:1549–1556
Farahani A, Correll CU (2012) Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry 73(4):486–496
Gallego JA, Bonetti J, Zhang J et al (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138:18–28
Gareri P, De Fazio P, Manfredi VG et al (2014) Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol 34(1):109–123
Harrow M, Jobe TH (2013) Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull 39(5):962–965
Hsieh PH, Hsiao FY, Gau SS, Gau CS (2013) Use of antipsychotics and risk of cerebrovascular events in schizophrenic patients: a nested case-control study. J Clin Psychopharmacol 33(3):299–305
Jarskog LF, Hamer RM, Catellier DJ (2013) Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 170(9):1032–1040
Jauhar S, McKenna PJ, Radua J et al (2014) Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 204:20–29
Kales HC, Kim HM, Zivin K et al (2012) Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry169(1): 71–79
Kane JM, Kishimoto T, Correll CU (2013) Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 12:216–226
Kelly TM, Daley DC, Douaihy AB (2012) Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 37(1):11–24
Khan A, Faucett J, Morrison S et al (2013) Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/ hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry 70(10):1091–1099
Kishimoto T, Agarwal V, Kishi T et al (2013a) Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 18(1):53–66
Kishimoto T, Nitta M, Borenstein M et al (2013b) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74(10):957–965
Kishimoto T, Robenzadeh A, Leucht C et al (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40:192–213
Klosterkötter J (2013) Prävention psychotischer Störungen. Nervenarzt 84(11):1299–1309
Kristensen D, Hageman I, Bauer J et al (2013) Antipsychotic polypharmacy in a treatment- refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. JECT 29:271–276
Leucht C, Heres S, Kane JM et al (2011) Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127(1–3):83–92
Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962
Leucht S, Samara M, Heres S et al (2014) Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40(2): 314-326
Lopez OL, Becker JT, Chang YF et al (2013) The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry 170(9): 1051-1058
Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35(7):1520-1530
Mahmood S, Booker I, Huang J, Coleman CI (2013) Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 33: 90-94
Nielsen J, Damkier P, Lublin H et al (2011) Optimizing clozapine treatment. Acta Psychiatr Scand 123:411–422
Nielsen J, Correll CU, Manu P et al (2013) Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 74:603–613
Osser DN, Roudsari MJ, Manschreck T (2013) The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry 21:18–40
Porcelli S, Balzarro B, Serretti A (2012) Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 22(3):165–182
Schennach R, Riesbeck M, Mayr A et al (2013) Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients? Acta Psychiatr Scand 127:474–481
Sommer IE, Begemann MJ, Temmerman A et al (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 38:1003–1011
Steinert T, Baier H, Fröscher W, Jandl M (2011) Epileptische Anfälle unter der Behandlung mit Antidepressiva und Neuroleptika. Fortschr Neurol Psychiatr 79(3):138–143
Taylor DM, Smith L, Gee SH et al (2012) Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand 125:15–24
Tiihonen J, Suokas JT, Suvisaari JM et al (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69:476–483
Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsades de Pointes. Dtsch Arztebl Int 108(41):687–693
Wolter DK (2009) Risiken von Antipsychotika im Alter, speziell bei Demenzen. Z Geronto-psychol -psychiatrie 22(1): 17–56
Wu CS, Wang SC, Gau SS et al (2013) Association of stroke with the receptor-binding profiles of antipsychotics-a case-crossover study. Biol Psychiatry 73(5):414–421
Wunderink L, Nieboer RM, Wiersma D et al (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70(9):913–920
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Benkert, O. (2015). Antipsychotika. In: Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54769-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-54769-0_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54768-3
Online ISBN: 978-3-642-54769-0
eBook Packages: Medicine (German Language)